|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||98.67 - 98.67|
|52-week range||88.75 - 112.65|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||17.78|
|Forward dividend & yield||3.86 (3.91%)|
|Ex-dividend date||05 May 2021|
|1y target est||N/A|
Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.
Actually, investors can have their cake and eat it too, balancing current income with principal appreciation.
Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline Combined efforts will work to build robust disease models while preserving privacy of large data sets from various research institutions and hospitals Collaboration to focus on four types of cancer PARIS – November 18, 2021 – Sanofi announced today an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programm